The Nigerian pharmaceutical industry has issued a “grave warning” regarding the “stifling impact” of the nation’s “near-total dependence” on imported “Active Pharmaceutical Ingredients” (APIs) and specialized medical inputs. During a “Pharma-Industrial Summit” in Lagos on Sunday, April 19, 2026, the leadership of the “Pharmaceutical Society of Nigeria” (PSN) and the “Manufacturers Association of Nigeria” (MAN) lamented that the “high cost of foreign exchange” and “protracted port delays” are “driving essential medicines out of the reach” of the average citizen. The industry maintained that while “local production” has recently hit a “50% milestone” for finished dosages, the “upstream supply chain” remains “dangerously foreign-reliant.”
The lamentation follows a recent “price hike” of over 200% for common medications used in the treatment of hypertension, diabetes, and malaria. Supporting context from the “Pharmaceutical Manufacturing Group of MAN” (PMG-MAN) indicates that Nigeria currently “imports over 95% of its APIs” from China and India. The Chairman of PMG-MAN, Pharm. Frank Muonemeh, noted that the “National Drug Policy” which targets “70% local manufacturing capacity” by 2027 is “under threat” due to the “lack of a dedicated pharmaceutical industrial park” and the “persistent power deficit.” He urged the Federal Government to “functionalize the ₦200 billion health sector intervention fund” and to provide “targeted tax holidays” for companies that invest in “local API synthesis.”
Stakeholder reactions to the industrial lamentation have been characterized by a “demand for urgent intervention” from the “National Agency for Food and Drug Administration and Control” (NAFDAC). The Director-General of NAFDAC, Professor Mojisola Adeyeye, has previously championed the “5+5 policy,” which compels foreign firms to “partner with local manufacturers” for the renewal of their product registrations. However, industry players argued that “regulatory pressure” must be accompanied by “fiscal incentives.” Conversely, the “Federal Ministry of Health” has asserted that the “ongoing ML3 (Maturity Level 3) certification” of Nigeria’s regulatory system will “attract more foreign direct investment” (FDI) into the sector, eventually “reducing the cost of production” through “technology transfer.”
Health and economic analysts observe that the “Pharma Paradox” where production is rising but prices are soaring is a result of “imported inflation.” Experts suggest that “self-sufficiency in drug production” is a “national security issue,” especially in a “post-pandemic world.” They argue that the government must “prioritize the pharmaceutical sector” in its “foreign exchange allocation” and “fix the logistics nightmare” at the Apapa and Tin-Can ports. Analyst Dr. Olusegun Ogundimo noted that “medicine is not a luxury,” adding that the “collapse of the local pharma industry” would leave Nigeria “vulnerable to a new wave of counterfeit and substandard drugs” from the “grey market.”
The broader implications of this industrial lamentation point toward a “looming health crisis” if the “cost of essential medicines” is not brought under control. By highlighting the “import-dependence,” the pharmaceutical industry is placing the government under “intense pressure” to deliver on its “Ease of Doing Business” promises. The move is also expected to trigger a “shift in consumer behavior,” as more Nigerians turn to “unverified herbal alternatives” due to the “unaffordability of orthodox drugs.” As the “National Health Authority” begins its “quarterly price monitoring” exercise, the focus remains on the “revitalization of the petrochemical industry” specifically the “Dangote and Port Harcourt refineries” to provide the “raw materials for API production.” For the Nigerian patient, the “pharma lamentation” is a “plea for life-saving affordability” in an increasingly expensive world.
